(+/-) N-(1,2-Dimethyl-1,2,3,4-tetrahydroisoquinolin-5-yl)-5-bromo-2,4-dimethoxybenzamide, hydrochloride | 213764-46-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: (+/-) N-(1,2-Dimethyl-1,2,3,4-tetrahydroisoquinolin-5-yl)-5-bromo-2,4-dimethoxybenzamide, hydrochloride
• 英文别名: Tcmdc-142734；5-bromo-N-(1,2-dimethyl-3,4-dihydro-1H-isoquinolin-5-yl)-2,4-dimethoxybenzamide;hydrochloride
• CAS: 213764-46-6
• 化学式: C₂₀H₂₃BrN₂O₃*ClH
• 分子量: 455.779
• InChiKey: YYRTYDBMESPMCN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.69
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  50.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (+/-) 5-Amino-1,2-dimethyl-1,2,3,4-tetrahydroisoquinoline 、 5-溴-2,4-二甲氧基苯甲酸 生成 (+/-) N-(1,2-Dimethyl-1,2,3,4-tetrahydroisoquinolin-5-yl)-5-bromo-2,4-dimethoxybenzamide, hydrochloride
  参考文献：
  名称：

  Anti-convulsant isoquinolyl-benzamide derivatives

  摘要：

  式(I)的化合物及其药学上可接受的盐，其中R1是氢、C1-6烷基（可选择地被羟基或C1-4烷氧基取代）、C1-6烯基、C1-6炔基、C1-6烷基CO—、甲酰基、CF3CO—或C1-6烷基SO2—；R2是氢或来自卤素、NO2、CN、N3、CF3O—、CF3S—、CF3CO—、三氟甲基二氮杂环丙基、C1-6烷基、C1-6烯基、C1-6炔基、C1-6全氟烷基、C3-6环烷基、C3-6环烷基-C1-4烷基、C1-6烷基O—、C1-6烷基CO—、C3-6环烷基O—、C3-6环烷基CO—、C3-6环烷基-C1-4烷基O—、C3-6环烷基-C1-4烷基CO—、苯基、苯氧基、苄氧基、苯甲酰基、苯基-C1-4烷基、C1-6烷基硫—、C1-6烷基SO2—、（C1-4烷基）2NSO2—、（C1-4烷基）NHSO2—、（C1-4烷基）2NCO—、（C1-4烷基）NHCO—或CONH2；或—NR5R6，其中R5是氢或C1-4烷基，R6是氢、C1-4烷基、甲酰基、—CO2C1-4烷基或—COC1-4烷基；或两个R2基共同形成饱和或不饱和的碳环，未取代或被—OH或═O取代；两个R3基和两个R4基各自独立地是氢或C1-6烷基，或两个R3基和/或两个R4基共同形成C3-6螺环烷基，前提是至少一个R3基和R4基不是氢，对癫痫和其他疾病的治疗和预防具有用处。

  公开号：

  US06277861B1

文献信息

• Anti-convulsant isoquinolyl-benzamide derivatives
  申请人：SmithKline Beecham, p.l.c.

  公开号：US06277861B1

  公开（公告）日：2001-08-21

  Compounds of formula (I) and pharmaceutically acceptable salts thereof, where R1 is hydrogen, C1-6alkyl (optionally substituted by hydroxy or C1-4alkoxy), C1-6alkenyl, C1-6alkynyl, C1-6alkylCO—, formyl, CF3CO— or C1-6alkylSO2—; R2 is hydrogen or up to three substituents selected from halogen, NO2, CN, N3, CF3O—, CF3S—, CF3CO—, trifluoromethyldiazirinyl, C 1-6?alkyl, C1-6alkenyl, C1-6alkynyl, C1-6perfluoroalkyl, C3-6cycloalkyl, C3-6cycloalkyl-C1-4alkyl-, C1-6alkylO—, C1-6alkylCO—, C3-6cycloalkylO—, C3-6cycloalkylCO—, C3-6cycloalkyl-C1-4alkylO—, C3-6cycloalkyl-C1-4alkylCO—, phenyl, phenoxy, benzyloxy, benzoyl, phenyl-C1-4alkyl-, C1-6alkylS—, C1-6alkylSO2—, (C1-4alkyl)2NSO2—, (C1-4alkyl)NHSO2—, (C1-4alkyl)2NCO—, (C1-4alkyl)NHCO— or CONH2; or —NR5R6 where R5 is hydrogen or C1-4alkyl, and R6 is hydrogen, C1-4alkyl, formyl, —CO2C1-4alkyl or —COC1-4alkyl; or two R2 groups together form a carbocyclic ring that is saturated or unsaturated and unsubstituted or substituted by —OH or ═O; and the two R3 groups and the two R4 groups are each independently hydrogen or C1-6alkyl or the two R3 groups and/or the two R4 groups together form a C3-6spiroalkyl group provided that at least one R3 and R4 group is not hydrogen, are useful in the treatment and prophylaxis of epilepsy and other disorders.

  式(I)的化合物及其药学上可接受的盐，其中R1是氢、C1-6烷基（可选择地被羟基或C1-4烷氧基取代）、C1-6烯基、C1-6炔基、C1-6烷基CO—、甲酰基、CF3CO—或C1-6烷基SO2—；R2是氢或来自卤素、NO2、CN、N3、CF3O—、CF3S—、CF3CO—、三氟甲基二氮杂环丙基、C1-6烷基、C1-6烯基、C1-6炔基、C1-6全氟烷基、C3-6环烷基、C3-6环烷基-C1-4烷基、C1-6烷基O—、C1-6烷基CO—、C3-6环烷基O—、C3-6环烷基CO—、C3-6环烷基-C1-4烷基O—、C3-6环烷基-C1-4烷基CO—、苯基、苯氧基、苄氧基、苯甲酰基、苯基-C1-4烷基、C1-6烷基硫—、C1-6烷基SO2—、（C1-4烷基）2NSO2—、（C1-4烷基）NHSO2—、（C1-4烷基）2NCO—、（C1-4烷基）NHCO—或CONH2；或—NR5R6，其中R5是氢或C1-4烷基，R6是氢、C1-4烷基、甲酰基、—CO2C1-4烷基或—COC1-4烷基；或两个R2基共同形成饱和或不饱和的碳环，未取代或被—OH或═O取代；两个R3基和两个R4基各自独立地是氢或C1-6烷基，或两个R3基和/或两个R4基共同形成C3-6螺环烷基，前提是至少一个R3基和R4基不是氢，对癫痫和其他疾病的治疗和预防具有用处。